C
Carlo Cattaneo
Publications - 27
Citations - 784
Carlo Cattaneo is an academic researcher. The author has contributed to research in topics: Safinamide & Parkinson's disease. The author has an hindex of 13, co-authored 22 publications receiving 606 citations.
Papers
More filters
Journal ArticleDOI
Improvement of motor function in early Parkinson disease by safinamide
Fabrizio Stocchi,Guy Arnold,Marco Onofrj,Hubert Kwieciński,Andrzej Szczudlik,Adèle Thomas,Ubaldo Bonuccelli,A. Van Dijk,Carlo Cattaneo,P. Sala,Ruggero Fariello +10 more
TL;DR: Results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Antonio Marzo,Lorenzo Dal Bo,Nunzia Ceppi Monti,Fabrizio Crivelli,Shevqet Ismaili,Carla Caccia,Carlo Cattaneo,Ruggero Fariello +7 more
TL;DR: Enteral absorption of the drug is linear and proportional to the doses administered, and pharmacokinetics of safinamide proved to be linearly and proportionally related to the administered doses.
Journal ArticleDOI
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
TL;DR: Results suggest that safinamide may have a positive effect on pain, one of the most underestimated non-motor symptoms in Parkinson’s Disease.
Journal ArticleDOI
Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
Fabrizio Stocchi,Laura Vacca,Paola Grassini,M. F. De Pandis,Giuseppe Battaglia,Carlo Cattaneo,Ruggero Fariello +6 more
TL;DR: It is suggested that these biochemical and symptomatic dose-dependent effects must be related to additional mechanisms of action, such as inhibition of glutamate release, increased dopamine release, or inhibition of dopamine re-uptake, which are under investigation and will pursue confirmation in controlled clinical trials.
Journal ArticleDOI
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
TL;DR: The present post-hoc analysis helps to provide a meaningful interpretation of the long-term effects of safinamide on dyskinesia and these results may be related tosafinamide state- and use-dependent inhibition of sodium channels and stimulated glutamate release, and are unlikely due to reduced dopaminergic stimulation.